Squarepoint’s Kyntra Bio KYNB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-12,186
Closed -$107K 4470
2025
Q4
$107K Sell
12,186
-4,184
-26% -$40.9K ﹤0.01% 4031
2025
Q3
$201K Buy
+16,370
New +$154K ﹤0.01% 3939
2025
Q1
Sell
-15,470
Closed -$205K 4841
2024
Q4
$205K Buy
+15,470
New +$144K ﹤0.01% 4455
2024
Q3
Sell
-6,517
Closed -$145K 4280
2024
Q2
$145K Buy
+6,517
New +$201K ﹤0.01% 3730
2023
Q4
Sell
-20,776
Closed -$448K 4145
2023
Q3
$448K Buy
20,776
+14,930
+255% +$586K ﹤0.01% 2873
2023
Q2
$395K Buy
5,846
+4,151
+245% +$1.72M ﹤0.01% 2789
2023
Q1
$791K Buy
+1,695
New +$897K ﹤0.01% 2039
2022
Q4
Sell
-2,731
Closed -$888K 3302
2022
Q3
$888K Buy
2,731
+1,842
+207% +$593K ﹤0.01% 1846
2022
Q2
$235K Buy
+889
New +$227K ﹤0.01% 2386
2022
Q1
Sell
-706
Closed -$249K 3063
2021
Q4
$249K Sell
706
-2,263
-76% -$705K ﹤0.01% 2561
2021
Q3
$759K Buy
2,969
+2,183
+278% +$774K ﹤0.01% 1727
2021
Q2
$524K Sell
786
-704
-47% -$406K ﹤0.01% 2091
2021
Q1
$1.29M Buy
1,490
+953
+177% +$1.01M 0.01% 1327
2020
Q4
$498K Sell
537
-462
-46% -$486K ﹤0.01% 1817
2020
Q3
$1.03M Buy
999
+720
+258% +$775K 0.01% 987
2020
Q2
$283K Buy
+279
New +$259K ﹤0.01% 1633
2020
Q1
Sell
-2,275
Closed -$2.44M 2071
2019
Q4
$2.44M Buy
+2,275
New +$2.32M 0.01% 788
2019
Q1
Sell
-2,067
Closed -$2.39M 2238
2018
Q4
$2.39M Buy
+2,067
New +$2.32M 0.03% 615
2017
Q4
Sell
-282
Closed -$379K 2164
2017
Q3
$379K Buy
+282
New +$297K 0.01% 1075
2017
Q1
Sell
-863
Closed -$462K 1642
2016
Q4
$462K Buy
+863
New +$431K 0.02% 881
2016
Q1
Sell
-1,484
Closed -$1.13M 1250
2015
Q4
$1.13M Buy
+1,484
New +$985K 0.12% 235

Other funds holding KYNB

Squarepoint's KYNB Position: Q1 2026 in Review

Squarepoint sold out of Kyntra Bio (KYNB) in Q1 2026, closing a stake of 12,186 shares — an estimated $107K sold.

Squarepoint first reported a position in KYNB in Q4 2015 and held it in 21 quarters. The position peaked at $2.44M in Q4 2019. 32 funds tracked by Wall St. Rank hold KYNB as of Q1 2026.

  • Squarepoint reported no remaining Kyntra Bio position as of Q1 2026 after selling out during the quarter.
  • Squarepoint sold 12,186 Kyntra Bio shares in Q1 2026, an estimated $107K.
  • Squarepoint first reported a position in Kyntra Bio in Q4 2015 and held it in 21 quarters.
  • Squarepoint's Kyntra Bio position peaked at $2.44M in Q4 2019.
  • 32 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.